Introduction: The efficacy of the applied model of laryngeal cancer treatment is measured by recurrence. Recurrence significantly reduces survival and determines the type of subsequent treatment. Objective: To determine the incidence of laryngeal cancer recurrence, the location of recurrence, and the definitive treatment of laryngeal cancer recurrence concerning different types of surgical treatments applied. Results: In the period from 2002 to 2017, 844 subjects with primary operated laryngeal squamous cell carcinoma were analyzed. Recurrence developed in 191/844 (22.6%) subjects. The mean recurrence time is 12.6 months. Supraglottic carcinoma is more likely to recur than glottic carcinoma 35.93% / 17.46%, p = 0.000. In N0 necks the recurrence rate is 14.42% and in N + necks it is 45.91, p = 0.000. In more advanced stages of the disease, the number of recurrence increases, p = 0.000. The most common area of recurrence is the neck with 45%, followed by local recurrence with 25.1%. Recurrence most often occurs in subjects with total laryngectomy and partial pharyngectomy, 50%. The most common development of regional recurrence is in the N3 category and extracapsular spread, 72.7%. The definitive treatment of recurrence usually involves radical neck dissection and total laryngectomy. Subjects with recurrence have a significantly lower three-year overall survival compared to those without recurrence, 47.6% / 92.3%, p = 0.000. Conclusion: Recurrence is expected in every fourth patient in the first 36 months following any type of surgical treatment of laryngeal carcinoma. The efficacy of treatment is directly related to recurrence. Recurrence is more common in more advanced stages of disease, extracapsular spread, and present metastases in the neck. Recurrence significantly reduces the overall survival of patients with laryngeal cancer.

The presence of regional metastases of laryngeal cancer differs depending on the location of the tumor and has an influence on the overall survival. The aim of this work is to analyze the frequency and characteristics of regional metastases T1 and T2 of laryngeal carcinoma in relation to the primary tumor location, and their effect on the overall survival. A retrospective study, conducted in the period between 2002 and 2012, that analyzed 445 patients who were surgically treated for laryngeal cancer of T1 and T2 category. The first group consisted of 397 patients without regional metastases, while the second group consisted of 48 patients with regional metastases. A three-year survival is followed, as well as the testing of potential predictors of outcomes by methods of regression. Regional metastases were present in 3.1% of patients with glottic carcinoma of T1 and T2 category, while 43.5% of patients with T1 and T2 supraglottis carcinoma had regional metastases. In the group with regional metastases, there is no statistically significant difference in the occurrence of extracapsular extension in relation to the tumor location, p = 0.7027. The three-year survival rate of patients without regional metastasis is 93.95%, while the survival of patients with regional metastases is 68,75%, p = 0.000. The tumor location (95% CI -1.4716 to -0.0497, P = 0.0369), and the presence of regional metastases (95% CI -1.6300 to -0.0253, P = 0.0443), were identified as predictors of outcomes by multifactorial analysis. Regional metastases in T1 and T2 laryngeal cancer are more common in patients with supraglottic carcinoma. The presence of regional metastases significantly reduces the three-year overall survival.